Andrea Casadei Gardini, Associate Professor at Vita-Salute San Raffaele University, shared a post on LinkedIn:
“Proud to have shared our clinical research at ESMO – European Society for Medical Oncology GI.
It was an honor to present three international studies on advanced Biliary Tract Cancer (BTC) in Munich, combining clinical trial insights with large-scale real-world evidence to optimize therapeutic standards.
Here is a quick summary of our posters:
- Poster 370P: Targeted Therapies in Advanced BTC After Chemoimmunotherapy Failure
The Focus: Evaluating efficacy and access to molecularly matched targeted therapies (e.g., IDH1, FGFR2, HER2, BRAF) after first-line progression.
Key Findings: 2L targeted therapies showed an extraordinary survival advantage, with a 67% reduction in the risk of death (HR 0.33) and a median OS of 24.8 vs. 11.3 months. This underscores the need for early genomic profiling to preserve the treatment window. - Poster 369P: Durvalumab-Based Regimens in Advanced BTC: LIVER-R Interim Analysis
The Focus: A global, observational real-world study (845 patients, 21 countries) assessing first-line Durvalumab + GemCis in routine clinical practice.
Key Findings: The regimen confirmed its robust real-world efficacy with a median OS of 13.2 months and a highly manageable safety profile, reinforcing it as the global standard of care. - Poster 467P: Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Eligibility Federica Lo Prinzi
The Focus: A massive analysis across 55 centers (1,358 patients) comparing patients meeting TOPAZ-1 trial criteria (‘in’) vs. those routinely excluded in practice (‘out’).
Key Findings: While ‘TOPAZ-1-out’ patients had a lower baseline prognosis (mOS 12.5 vs 16.1 months), the survival benefit added by Durvalumab remained comparable across both groups, supporting its use beyond strict trial boundaries.
A heartfelt thank you to all co-authors (in particolar Lorenza Rimassa and Lorenzo Fornaro).”
Other articles featuring Andrea Casadei Gardini and ESMO Gi on OncoDaily.
